Image
Recommendation
Adjuvant chemotherapy – Indications #2
The choice of neoadjuvant or adjuvant chemotherapy should be determined by a patient’s comorbidities, physical function, and degree of frailty, and not by gene mutation status or age alone.
Base the type of neoadjuvant/adjuvant chemotherapy for women diagnosed with breast cancer with a BRCA1/2 mutation on similar considerations for women with early breast cancer not attributable to a BRCA1/2 mutation.
Body of evidence provides some support for recommendation(s), but care should be taken in its application
How this guidance was developed
This recommendation was adapted from the CA 2014 guidelines (Australia). The source recommendation was based on a systematic review of the evidence conducted to April 2012 and was graded 'C' (using NHMRC methods) by the source guideline authors. The source recommendation was adapted by expanding the patient population from ‘women’ to ‘all patients’, by replacing ‘BRCA1/2 status’ with 'gene mutation status’, and by including age as a factor.
Related guidance by topic
Adjuvant chemotherapy – Indications #2
Recommendation
The choice of neoadjuvant or adjuvant chemotherapy should be determined by a patient’s comorbidities, physical function, and degree of frailty, and not by gene mutation status or age alone.
Principles in action
Patient-centred care
Image
Multidisciplinary care
This recommendation was adapted from the CA 2014 guidelines (Australia). The source recommendation was based on a systematic review of the evidence conducted to April 2012 and was graded 'C' (using NHMRC methods) by the source guideline authors. The source recommendation was adapted by expanding the patient population from ‘women’ to ‘all patients’, by replacing ‘BRCA1/2 status’ with 'gene mutation status’, and by including age as a factor.
Related guidance by topic
Image
